| Abstract [eng] |
This comprehensive literature review investigates Disease Modifying Osteoarthritis Drugs aiming to modify osteoarthritis progression. Focusing on cartilage-driven endotypes, the review evaluates drugs such as Sprifermin, Lorecivivint, MIV-711, S201086/GLPG1972, and Metformin. The FORWARD study emphasises the potential of Sprifermin for lasting structural changes and highlights its possible role in transforming osteoarthritis treatment. Lorecivivint shows significant pain relief, but is insufficient in improving joint space width, so further studies are needed to contribute to a more nuanced understanding of osteoarthritis treatment. MIV-711, a Cathepsin K inhibitor, exhibits promise in attenuating femoral cartilage loss and bone area progression, offering a potential disease modifying effect. S201086/GLPG1972, an ADAMTS-5 inhibitor, faces challenges in reducing cartilage loss but maintains a well-tolerated safety profile, calling for further exploration. Metformin displays potential in diminishing knee cartilage loss and lowering replacement risks, introducing a unique perspective in the context of osteoarthritis treatment. Despite hurdles, Sprifermin and MIV-711 offer potential for structural modification and underline the need for ongoing research to refine personalized treatment guidelines and biomarker understanding in the treatment in osteoarthritis. The lack of approved Disease Modifying Osteoarthritis Drugs for osteoarthritis treatment accentuates the ongoing challenges to an all-encompassing comprehension of the pathophysiology of osteoarthritis and thereby difficulties of a personalized medicine that would enable comprehensive care for osteoarthritis. |
